As expected, Radient Pharmaceuticals granted favorable decision

Print E-mail
By Staff and ordering cialis gel Wire Reports   
Thursday, 21 April 2011 08:17
Radient Pharmaceuticals Corporation (AMEX:RPC) announced today that a Listing Qualifications Panel of the pfizer viagra 50mg NYSE Amex Committee on Securities has issued a favorable decision and granted RPC's request for continued listing on the canadian pharmacy cialis NYSE Amex Exchange . This decision followed RPC's hearing before the online cheap viagra Panel on April 14, 2011. 

As a threshold matter, prior to the viagra uk granting of the extension, RPC was required to satisfactorily address at the canada meds viagra hearing the brand cialis for sale concerns raised by the Staff of NYSE Regulation, Inc. that RPC had overstated the online cialis scope of its collaboration agreement with Mayo Validation Support Services.

Pursuant to the Panel's decision, on or before June 23, 2011, the Company is required to demonstrate compliance with all applicable requirements for continued listing and, in particular, must complete the viagra online 50mg following actions: file its Annual Report on Form 10-K with the Securities and viagra en gel Exchange Commission; hold its planned stockholders' meeting at which directors will be elected; and, complete its plans for raising additional equity capital, thereby demonstrating its compliance with the Exchange's stockholders' equity requirement of $6 million and viagra prices the lack of any financial impairment.

A special report with more details about what transpired at the meeting with the Listing Qualifications Panel of the NYSE Amex Committee on Securities will follow. In the meantime, we invite you to read the special report issued to our premium subscribers on Wednesday.





BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 
BioMedReports FDA Approves ELELYSO(TM); Auxilium To Present CCH Data For AUX-CC-867 MULTICORD: Below is a look at some of t... http://t.co/38kIFa08zF
9hreplyretweetfavorite
BioMedReports Team identifies possible bacterial drivers of inflammatory bowel diseases http://t.co/kqjKEssVCp
11hreplyretweetfavorite
BioMedReports Healthcare Review: Tekmira Pharmaceuticals, Repros Therapeutics, Edap Tms SA, Covidien, Pfizer: U.S. stocks s... http://t.co/w5lIcDzpoZ
14hreplyretweetfavorite
navigation
Benzinga.com supporter Seeking Alpha Certified